Lineage Cell Therapeutics, Inc. (LCTX) Presents at H.C. Wainwright 27th

Sara Nik
Research Analyst

And welcome to our next session. I’m the moderator, Sara Nik, an Equity Research VP at H.C. Wainwright. And it’s my pleasure to introduce our next presenter, Brian Culley, CEO of Lineage Cell Therapeutics, a clinical stage biotechnology company developing novel cell therapies for neurological and ophthalmic conditions. Brian, the floor is yours.

Brian Culley
CEO, President & Director

Thank you so much, and good morning, everybody. It’s a pleasure to be here. All right. Next slide. So as we’re a publicly traded company and I may make some forward-looking statements, please refer to our safe harbor information filed at clinical trials — excuse me, that was ironic — sec.gov. You can also visit clinicaltrials.gov.

All right. So Lineage Cell Therapeutics. I’m going to go very quickly today because I want to squeeze in a couple of new things that you haven’t heard presented from the company before. We had some announcements. But as a general matter, Lineage Cell Therapeutics is dedicated to the manufacture and delivery of specific cell types. And we are doing this in order to address conditions and indications where the loss of a certain cell type gives rise to the disease. The highest and best use case for this to date for us has been in the setting of dry age-related macular degeneration. This disease, the hallmark is the loss of RPE cells. We manufacture RPE cells in the laboratory and deliver them to patients in order to restore the function that’s lost in that condition.

The pipeline, this is